VDL-309

N/A

Report date: 2026/02/03 17:47:39

Base Information

Drug NameVDL-309
Drug Alias NameVDL-309VDL309
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Complement component C1q receptor
TargetsComplement component C1q receptor
Therapy Area/IndicationsBrain metastasesHigh-Grade Glioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVascurie AB
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsBrain metastasesHigh-Grade Glioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A